The FDA has accepted Saol Therapeutics' NDA for SL1009 (sodium dichloroacetate) with Priority Review for treating Pyruvate Dehydrogenase Complex Deficiency (PDCD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.